Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Feb 15;11(1):42.
doi: 10.1186/s13256-016-1181-3.

R248G cystic fibrosis transmembrane conductance regulator mutation in three siblings presenting with recurrent acute pancreatitis and reproductive issues: a case series

Affiliations
Case Reports

R248G cystic fibrosis transmembrane conductance regulator mutation in three siblings presenting with recurrent acute pancreatitis and reproductive issues: a case series

Seiichi Villalona et al. J Med Case Rep. .

Abstract

Background: Mutational combinations of the cystic fibrosis transmembrane conductance regulator, CFTR, gene have different phenotypic manifestations at the molecular level with varying clinical consequences for individuals possessing such mutations. Reporting cystic fibrosis transmembrane conductance regulator mutations is important in understanding the genotype-phenotype correlations and associated clinical presentations in patients with cystic fibrosis. Understanding the effects of mutations is critical in developing appropriate treatments for individuals affected with cystic fibrosis, non-classic cystic fibrosis, or cystic fibrosis transmembrane conductance regulator-related disorders. This is the first report of related individuals possessing the R248G missense cystic fibrosis transmembrane conductance regulator mutation and we present their associated clinical histories.

Case presentation: All three patients are of Spanish descent. Deoxyribonucleic acid analysis revealed that all three siblings possessed a novel c.742A>G mutation, resulting in a p.Arg248Gly (R248G) amino acid change in exon 6 in trans with the known N1303K mutant allele. Case 1 patient is a 39-year-old infertile man presenting with congenital unilateral absence of the vas deferens and recurrent episodes of epigastric pain. Case 2 patient is a 32-year-old woman presenting with periods of infertility, two previous spontaneous abortions, recurrent epigastric pain, and recurrent pancreatitis. Case 3 patient is a 29-year-old woman presenting with recurrent pancreatitis and epigastric pain.

Conclusions: We report the genotype-phenotype correlations and clinical manifestations of a novel R248G cystic fibrosis transmembrane conductance regulator mutation: congenital unilateral absence of the vas deferens in males, reduced female fertility, and recurrent acute pancreatitis. In addition, we discuss the possible functional consequences of the mutations at the molecular level.

Keywords: CFTR; Congenital absence of vas deferens; Genotype-phenotype; Missense mutation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cystic fibrosis transmembrane conductance regulator protein. a Two-dimensional model of the cystic fibrosis transmembrane conductance regulator protein with major functional components. b Wild-type intracellular loop 2/cellular loop 2 primary protein structure depicting amino acid properties. c Intracellular loop 2/cellular loop 2 regions clinically associated with congenital bilateral absence of the vas deferens or congenital unilateral absence of the vas deferens resulting from a reported missense mutation. ICL2/CL2 intracellular loop 2/cellular loop 2, NBD1 nucleotide-binding domain 1, NBD2 nucleotide-binding domain 2

References

    1. Derichs N. Targeting a genetic defect: Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev. 2013;22:58–65. doi: 10.1183/09059180.00008412. - DOI - PMC - PubMed
    1. des Georges M, Guittard C, Altiéri JP, Templin C, Sarles J, Sarda P, Claustres M. High heterogeneity of CFTR mutations and unexpected low incidence of cystic fibrosis in the Mediterranean France. J Cyst Fibros. 2004;3:265–72. doi: 10.1016/j.jcf.2004.04.008. - DOI - PubMed
    1. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10:86–102. doi: 10.1016/S1569-1993(11)60014-3. - DOI - PubMed
    1. Tsai M, Li M, Hwang T. Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channel. J Gen Physiol. 2010;135:399–414. doi: 10.1085/jgp.201010399. - DOI - PMC - PubMed
    1. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest. 2011;139:1480–90. doi: 10.1378/chest.10-2077. - DOI - PubMed

Publication types

Substances